Escitalopram Does Not Reduce Hospitalisation, Death, or Improve Mood for Heart Failure Patients With Depression
Previous meta-analysis indicates that depression prevalence in patients with heart failure is 10% to 40%, depending on disease severity. Depression has been shown to be an independent predictor of mortality and rehospitalisation in patients with heart failure, with incidence rates increasing in parallel with depression severity. Long-term efficacy and safety of selective serotonin reuptake inhibitors (SSRIs), which are widely used to treat depression, is unknown for patients with heart failure and depression.
For this study, 372 patients with chronic heart failure with reduced ejection fraction and depression were randomly assigned to receive escitalopram or matching placebo in addition to optimal heart failure therapy. During a median participation time of 18.4 months (n = 185) for the escitalopram group and 18.7 months (n = 187) for the placebo group, the primary outcome of death or hospitalisation occurred in 116 (63%) patients and 119 (64%) patients, respectively. There was no significant improvement on a measure of depression for patients in the escitalopram group.
“These findings do not support the use of escitalopram in patients with chronic systolic heart failure and depression,” the authors write.
DG News saves you time by delivering a short list of medical developments worthy of your time and attention. Our advanced algorithms rank clinical content based on hundreds of data points to surface the most important medical advances impacting your practice each week.